Related Experiment Video
Updated: Jul 14, 2025
05:53
Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Published on: July 6, 2013
15.0K
Vaccine value profile for cytomegalovirus
Suresh B Boppana1, Michiel van Boven2, William J Britt3
1Departments of Pediatrics and Microbiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Vaccine
|October 8, 2023
Summary
Cytomegalovirus (CMV) vaccines are a high priority for preventing congenital CMV infection and its associated disabilities. Candidate vaccines show promise, with potential licensure within five years to reduce the global disease burden.
Area of Science:
- Public Health
- Infectious Diseases
- Vaccinology
Background:
- Congenital Cytomegalovirus (cCMV) is a leading cause of congenital malformations and developmental disabilities, including sensorineural hearing loss (SNHL).
- The US National Institute of Medicine prioritized CMV vaccine development due to the significant disease burden of cCMV.
- Global cCMV prevalence is underestimated, as most infected infants (85-90%) are asymptomatic but can develop SNHL later.
Purpose of the Study:
- To provide a comprehensive assessment of the potential public health, economic, and societal value of CMV vaccines.
- To inform stakeholders about the current state of CMV vaccine development and identify knowledge gaps.
Main Methods:
- A vaccine value profile (VVP) was developed by a multidisciplinary working group of subject matter experts.
- The VVP utilized existing, publicly available data on CMV, cCMV, and vaccine candidates.
- The assessment focused on preventing or reducing the cCMV disease burden.
Main Results:
- Several CMV vaccine candidates are in development, with one in phase 3 trials.
- Vaccine licensure is feasible within the next five years.
- Modeling studies indicate substantial benefits from various CMV vaccine strategies in reducing cCMV.
Conclusions:
- CMV vaccine development is a critical public health priority with promising candidates nearing licensure.
- Effective CMV vaccines have the potential to significantly reduce the global burden of congenital CMV infection and its long-term sequelae.
- Further research and strategic implementation are needed to maximize the value of CMV vaccines.
